Close Menu

spatial genomics

The Pleasanton, California-based firm reported $71.9 million in revenues but missed the consensus Wall Street estimates for quarterly revenues as well as loss per share.

The firm remains on track to ship its first NGS-enabled instruments, along with its new cancer transcriptome atlas panel covering more than 1,800 genes, during Q3.

The company intends to use most of the proceeds to pay off debts and associated fees, and the rest to support its platform and consumables development. 

The company intends to use most of the proceeds to pay off debts and associated fees, and the rest to support its platform and consumables development.

The firm said it took in $33.6 million in product and service revenue in the quarter, a 42 percent increase from $23.6 million in Q4 2018.

The Cambridge, Massachusetts-based firm also said it tacked on $3 million to its Series B financing round for a total of $30 million.

The company plans to offer four new products by the end of the year, including four targeted transcriptomic panels and IHC compatibility for Visium.

Though 10x will phase out its linked reads technology, it plans to introduce targeted RNA-seq for Chromium and FFPE sample compatibility for Visium.

The single-cell analysis and spatial genomics company reported $75.3 million in Q4 revenues. Full year revenues grew 68 percent to $245.9 million.

Single Technologies is working on a new sequencing platform with faster imaging and smaller flow cells that will harness existing chemistries.

Pages

Researchers have developed a robotic lab assistant, the Verge reports.

CBC News reports Canada's Supreme Court is to rule on the constitutionality of the country's genetic non-discrimination law today.

The Associated Press reports the World Health Organization is sending experts to China to investigate the animal source of SARS-CoV-2.

In Science this week: atlas of affected cell populations in idiopathic pulmonary fibrosis, and more.